Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Veterinary Microbiology

Multiplex PCR Assay for Unequivocal Differentiation of Actinobacillus pleuropneumoniae Serovars 1 to 3, 5 to 8, 10, and 12

Janine T. Bossé, Yanwen Li, Øystein Angen, Lucy A. Weinert, Roy R. Chaudhuri, Matthew T. Holden, Susanna M. Williamson, Duncan J. Maskell, Alexander W. Tucker, Brendan W. Wren, Andrew N. Rycroft, Paul R. Langford
E. Munson, Editor
Janine T. Bossé
aSection of Paediatrics, Department of Medicine, Imperial College London, St. Mary's Campus, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanwen Li
aSection of Paediatrics, Department of Medicine, Imperial College London, St. Mary's Campus, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Øystein Angen
bNorwegian Veterinary Institute, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy A. Weinert
cDepartment of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy R. Chaudhuri
cDepartment of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew T. Holden
dThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna M. Williamson
eAnimal Health Veterinary Laboratories Agency (AHVLA), Rougham Hill, Suffolk, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan J. Maskell
dThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander W. Tucker
dThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brendan W. Wren
fDepartment of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Rycroft
gDepartment of Pathology and Pathogen Biology, The Royal Veterinary College, Hawkshead Campus, Hertfordshire, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul R. Langford
aSection of Paediatrics, Department of Medicine, Imperial College London, St. Mary's Campus, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Munson
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00685-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

An improved multiplex PCR, using redesigned primers targeting the serovar 3 capsule locus, which differentiates serovars 3, 6, and 8 Actinobacillus pleuropneumoniae isolates, is described. The new primers eliminate an aberrant serovar 3-indicative amplicon found in some serovar 6 clinical isolates. Furthermore, we have developed a new multiplex PCR for the detection of serovars 1 to 3, 5 to 8, 10, and 12 along with apxIV, thus extending the utility of this diagnostic PCR to cover a broader range of isolates.

INTRODUCTION

Actinobacillus pleuropneumoniae is a major cause of morbidity and mortality due to respiratory disease in pigs and is responsible for substantial economic losses worldwide (1). There are 15 serovars of A. pleuropneumoniae (2), based on the presence of surface carbohydrates, principally capsules, with their prevalence varying between geographic regions. For example, serovars 1 and 5 are common in North and South America, and serovar 2 is common in Europe (reviewed in reference 3; see references therein), whereas these serovars are absent or rare in the United Kingdom (4). Differences in virulence and immunogenicity have been reported for different serovars (5), though within serovars, isolates tend to be clonal (6, 7). Accurate serotyping is essential for informed diagnosis, epidemiological investigation of outbreaks, and detection of the emergence of serovars previously not found, or rare, within a geographical region. The serovar of an isolate is classically determined using antibody-based tests (3). However, cross-reactivity is a major limitation and has been reported between serovars 1 and 9 (8), serovars 4 and 7 (9), and serovars 3, 6, and 8 (reviewed in reference 10). Thus, multiplex PCRs based on capsule loci have been developed, including those for serovars 2, 5, and 6 (11), 1, 2, and 8 (12), and 1, 7, and 12 (13). We have additionally devised a multiplex PCR that determines whether an isolate is serovar 3, 6, or 8 (10). The latter multiplex PCR amplifies a fragment of the A. pleuropneumoniae-specific apxIV gene and serovar 3-, 6-, and 8-specific sequences derived from the capsule loci. In recent years, we have observed in our collection (and others have reported [14]) a double- banding pattern in some isolates, so that it is not possible to distinguish between serovars 3 and 6. In this study, we (i) discerned the genetic reason for the aberrant serovar 3/6 double-banding pattern, (ii) developed a new serovar 3-6-8 PCR with modified serovar 3 primers that eliminate the aberrant pattern, and (iii) extended that PCR to include a further six serovars commonly found throughout the world. This includes the detection of serovar 10, for which a capsule locus-based PCR has not been described previously.

MATERIALS AND METHODS

Bacterial strains.In this study, we used 15 reference A. pleuropneumoniae strains (see reference 10 for details), as well as a collection of 334 A. pleuropneumoniae clinical isolates from Denmark (n = 166), the United Kingdom (n = 154) (including 9 serovar 6 isolates that previously tested positive for serovars 3 and 6), Cyprus (n = 6), Switzerland (n = 6), and China (n = 2). All the isolates were previously typed serologically and/or by capsule-specific PCR. In addition, 31 strains of other porcine-associated bacterial species were tested as negative controls These included Actinobacillus suis (n = 5), Actinobacillus minor (n = 3), Actinobacillus porcitonsillarum (n = 3), Actinobacillus porcinus (n = 3), Actinobacillus indolicus (n = 3), Haemophilus parasuis (n = 5), Pasteurella multocida (n = 3), Bordetella bronchiseptica (n = 2), Mycoplasma hyopneumoniae (n = 3), and Streptococcus suis P1/7 (n = 1).

Capsule regions of MIDG2472 and 405.In this study, we have generated shotgun genome sequence data for the A. pleuropneumoniae serovar 6 United Kingdom clinical isolate MIDG2472, which shows the double-banding pattern using the 3-6-8 multiplex PCR previously described (10), and for the serovar 8 reference strain, 405. A shotgun genome sequence was generated from genomic DNA prepared using the Blood and Tissue DNeasy kit (Qiagen) per the manufacturer's instructions. Libraries were prepared from 5 μg genomic DNA by standard protocols (15, 16) and paired-end sequencing was performed at the Wellcome Trust Sanger Institute (Cambridge) on an Illumina HiSeq 2000 analyzer for 75 cycles. Draft genome sequences were assembled using VelvetOptimiser 2.2.0 (17) and capsule loci were identified using BLAST searches (18). The complete capsule loci for the other serovar strains (1, 2, 3, 5, 6, 10, and 12) were identified from the available whole-genome sequences (19–21).

Multiplex PCRs.The primers used in this study are detailed in Table 1. The binding sites for the serovar 3, 6, and 8 primers in the respective capsule loci are shown in Fig. 1. Our original multiplex PCR for serovars 3, 6, and 8 was carried out as previously described (10). For the new multiplex PCR, the Qiagen Multiplex PCR Plus kit was used according to the manufacturer's instructions (Qiagen). Each reaction mixture contained 25 μl multiplex PCR master, 5 μl CoralLoad dye, 5 μl genomic DNA, 10 pairs of primers (each 10 pmol), and 13 μl water to a final volume of 50 μl. Genomic DNA extracted using the DNeasy blood and tissue kit (Qiagen) or present in boiled bacterial lysates prepared as described by Jessing et al. (11) was used as the DNA template for PCR amplification. Targeted gene amplification was initiated at 95°C for 5 min to activate the HotStar Taq plus DNA polymerase, followed by 25 cycles of 3-step cycling of denaturation at 95°C for 30 s, annealing at 61°C for 90 s, extension at 72°C for 2 min, and a final extension at 68°C for 15 min. PCR products were separated by 1.5% agarose gel electrophoresis, stained with ethidium bromide, and analyzed using a Gel Doc EI imager (Bio-Rad).

View this table:
  • View inline
  • View popup
TABLE 1

Primers used in this study

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Location of primers within capsule loci of A. pleuropneumoniae serovar (Sero) 3, 6, and 8 strains. See Table 1 for oligonucleotide sequences of primers.

Nucleotide sequence accession numbers.The DNA sequences of the capsule loci of strains MIDG2472 and 405 have been deposited in GenBank under accession numbers KJ685492 and KJ685493 , respectively.

RESULTS AND DISCUSSION

The first aim of this study was to determine the reason for the amplification of bands indicating serovars 3 and 6 in some serovar 6 clinical isolates. In our original multiplex PCR, the serovar 6-specific primers (AP6F and AP6R) were derived from a previously published PCR (11, 12). Their binding sites in the serovar 6 capsular locus are shown in Fig. 1. The serovar 3 primers (AP3NF and AP3NR) were designed to amplify a 921-bp fragment from cps3A (APJL_1614) to cpxD (APJL_1615), and the serovar 8 primers (AP8NF and AP8NR) were designed to amplify a 1,106-bp fragment from cps8A to cps8B, as indicated in Fig. 1 for the serovar 3 and serovar 8 capsule loci. Our original serovar 3 primers (AP3NF and AP3NR) were based on a DNA sequence that we obtained from a chromosome-walking strategy using serovar 3 reference strain S1421 prior to the availability of the serovar 3 JL03 whole-genome sequence (10, 22). AP3NF and AP3NR amplify a 921-bp PCR product in S1421 (serovar 3) but not the serovar 6 Femo reference strain (Fig. 2A, lanes 1 and 2), whereas MIDG2472 amplifies this 921-bp band as well as the serovar 6-indicative 718-bp product (Fig. 2A, lane 3). DNA sequence analysis of the capsule locus of MIDG2472 and Femo provides an explanation for the aberrant double-banding pattern. In MIDG2472, in addition to the serovar 6-specific region amplified by AP6F and AP6R, there are perfect binding sites for AP3NF and AP3NR (Fig. 1 and 3). In Femo, there is a binding site for AP3NR, but that for AP3NF is partially redundant (Fig. 3), such that, under the PCR conditions used, no amplification occurs. In strain 405 (serovar 8), the AP3NR binding sequence is partially redundant (Fig. 3), such that amplification with AP3NF does not occur. Thus, in Femo, only a 718-bp serovar 6-specific amplicon is present, while in MIDG2472 there is an additional 921-bp amplicon resulting from binding of the serovar 3 primer pair. In summary, the aberrant serovar 3/6 banding pattern results from the lack of specificity of the serovar 3 primers AP3NF and AP3NR in some serovar 6 isolates, such as MIDG2472. The two Japanese isolates with aberrant banding patterns were also found to have perfect priming sites for AP3NF and AP3NR (14). Thus, to eliminate the aberrant 3/6 banding pattern, we have reformulated our original 3-6-8 PCR by replacement of the serovar 3 primers. All other primers and PCR conditions were otherwise as described originally (10). The new serovar 3 PCR primers AP3DF and AP3DR are designed to amplify a 520-bp fragment of the serovar 3-specific APJL_1611 (cpsD) gene (Fig. 1). A comparison of old and new PCRs with the serovar 3, 6, and 8 reference strains and serovar 6 “aberrant” strain (MIDG2472) is shown in Fig. 2. The new PCR (Fig. 2B) eliminates the aberrant banding, there being amplicons at 520 bp, 718 bp, and 1,106 bp specific for serovar 3, 6, and 8 strains/isolates, respectively. For the unequivocal differentiation of serovar 3, 6, and 8 A. pleuropneumoniae isolates, we recommend that investigators use the modified PCR described in this study.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Comparison of original (10) and new (this study) multiplex PCRs for detection of A. pleuropneumoniae serovars 3, 6, and 8. (A) Original multiplex PCR for amplification of apxIV (418 bp), serotype 3 (921 bp), serotype 6 (718 bp), and serotype 8 (1,106 bp) amplicons. (B) New multiplex PCR for amplification of apxIV (418 bp), serotype 3 (520 bp), serotype 6 (718 bp), and serotype 8 (1,106 bp) amplicons. Lane M, 100-bp ladder; lanes 1, serovar 3, S1421; lanes 2, serovar 6, Femo; lanes 3, serovar 6, MIDG2472; lanes 4, serovar 8, 405.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Alignment of the binding sites for primers AP3NF and AP3NR within the capsule loci of A. pleuropneumoniae serovar (Sero) 3, 6, and 8 strains. There are perfect binding sites for the AP3NF primer in the cpxD gene in strains JL03, MIDG2472, and 405. In strain Femo, the cpxD sequence differs slightly at the target site, such that the primer AP3NF does not bind. There are perfect binding sites for AP3NR in the cpsA gene in strains JL03, Femo, and MIDG2472. In strain 405, the cpsA sequence differs slightly at the target site, such that the primer AP3NR does not bind.

Next, the utility of the new serovar 3-6-8 PCR was extended to include serovars 1, 2, 5, 7, 10, and 12, which are more prevalent in some countries, but which are either absent (as is the case for serovars 1 and 5) or are comparatively rare in the United Kingdom. Serovar-specific sequences were derived from whole-genome sequences: GenBank accession numbers ADOD00000000 (4074, serovar 1), ADOE00000000 (S1536, serovar 2), CP000687 (JL03, serovar 3), ADOF00000000 (M62 serovar 4), CP000569 (L20, serovar 5), ADOG00000000 (Femo, serovar 6), CP001091 (AP76, serovar 7), ADOI00000000 (CVJ13261, serovar 9), ADOJ00000000 (D13039, serovar 10), ADOK00000000 (56153, serovar 11), ADOL00000000 (1096, serovar 12), and ADOM00000000 (N273, serovar 13). The details of the primer pairs that were derived for use in the 9-serovar multiplex PCR are provided in Table 1. The 9-serovar multiplex PCR was initially tested against the A. pleuropneumoniae reference strains (Fig. 4). As expected, all of the reference strains had an apxIV amplicon of 418 bp, as reported previously (10), and appropriate serotype-specific amplicons of predicted sizes were detected for the reference strains of serovars 1 to 3, 5 to 8, 10, and 12. Subsequently, the PCR was evaluated using clinical A. pleuropneumoniae isolates, as well as other actinobacilli, other Pasteurellaceae, and other major pathogens of pigs. Additionally, virtual PCRs were carried out on available genomes of the species investigated, where available. A breakdown of the PCR results for clinical A. pleuropneumoniae isolates is shown in Table 2. Serovar designation of isolates had been carried out either by PCR, as described previously, or by antibody-based serotyping. All of the 334 clinical A. pleuropneumoniae strains tested amplified the predicted serovar amplicons. Five strains were positive for the serovar 1 amplicon but did not amplify the 418-bp apxIV band. These strains were subsequently tested for apxIV using the primers oAPXIVA-TSP1 and oAPXIVA-TSP2 (23), and each strain produced a 423-bp band indicating that apxIV is present (with no ISApl1 insertion). We recommend that where an isolate is strongly suspected to be A. pleuropneumoniae and there is a lack of either apxIV or a serovar-specific amplicon in our 9-serovar PCR, researchers retest the isolate with alternate A. pleuropneumoniae-specific primers such as those indicated above. If the isolate is confirmed as A. pleuropneumoniae, it is likely that its serovar is not covered by our multiplex PCR. While other multiplex PCRs have been reported for all but serovar 10, these have typically involved coverage of three serovars (see references 11–13). None have been described that include serovar 10 as described here. Serovar 10 isolates have been reported in Canada, Denmark, Germany, Hungary, Spain (3), and the United Kingdom (4), although not as one of the prevalent serovars.

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

Multiplex PCR for detection of A. pleuropneumoniae serovars 1 to 3, 5 to 8, 10, and 12 and apxIV. An apxIV (418 bp) amplicon is detected in all 15 serovars, while serovar-specific amplicons are detected for serovar 1 (959 bp), serovar 2 (247 bp), serovar 3 (520 bp), serovar 5 (825 bp), serovar 6 (718 bp), serovar 7 (600 bp), serovar 8 (1,106 bp), serovar 10 (183 bp), and serovar 12 (347 bp). Lane M, 100-bp ladder; lane 1, 4074T; lane 2, S1536; lane 3, S1421; lane 4, M62; lane 5, L20; lane 6, Femo; lane 7, WF83; lane 8, 405; lane 9, CVJ13261; lane 10, D13039; lane 11, 56153; lane 12, 8329; lane 13, N-273; lane 14, 3906; lane 15, HS143.

View this table:
  • View inline
  • View popup
TABLE 2

Number of serovar-specific and apxIV amplicons detected in 334 clinical isolates of A. pleuropneumoniae using the multiplex PCR

The specificity of the multiplex PCR was further tested using 31 isolates representing porcine-associated bacterial species other than A. pleuropneumoniae, which were derived from our collection and have been assigned at the species level by conventional biochemical testing. None of these strains produced any amplicons with the new 9-serovar multiplex PCR.

In summary, we have developed a single-tube multiplex PCR that unequivocally differentiates A. pleuropneumoniae serovars 1 to 3, 5 to 8, 10, and 12. With the use of our well-characterized collection of A. pleuropneumoniae isolates and other porcine-associated bacterial species, the new PCR was 100% sensitive and specific for serotyping. In regard to the United Kingdom, the PCR covers all of the serovars (2, 3, 6, 7, 8, 10, and 12) that were previously reported (4), although a single serovar 9 isolate has subsequently be found (24).

The inclusion of apxIV-specific primers should allow for detection of A. pleuropneumoniae serovars not included in the multiplex PCR, though we have identified a small number (5/334) of strains that failed to produce the predicted 418-bp amplicon. In those strains, an apxIV band was obtained with alternate primers. Although we did not investigate further, the new multiplex PCR could be adapted to detect relevant serotypes found in different countries by excluding or including capsule-specific primers for other serovars as required.

ACKNOWLEDGMENTS

This work was supported by a Longer and Larger (LoLa) grant from the Biotechnology and Biological Sciences Research Council (grant numbers BB/G020744/1, BB/G019177/1, BB/G019274/1, and BB/G003203/1) and the United Kingdom Department for Environment, Food and Rural Affairs and Zoetis awarded to the Bacterial Respiratory Diseases of Pigs-1 Technology (BRaDP1T) consortium. The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

The BRaDP1T Consortium comprises Duncan J. Maskell, Alexander W. (Dan) Tucker, Sarah E. Peters, Lucy A. Weinert, Jinhong (Tracy) Wang, Shi-Lu Luan, and Roy R. Chaudhuri (University of Cambridge); Andrew N. Rycroft, Gareth A. Maglennon, and Dominic Matthews (Royal Veterinary College); Brendan W. Wren, Jon Cuccui, and Vanessa Terra (London School of Hygiene and Tropical Medicine); and Janine T. Bossé, Yanwen Li, and Paul R. Langford (Imperial College London).

FOOTNOTES

    • Received 19 March 2014.
    • Returned for modification 31 March 2014.
    • Accepted 15 April 2014.
    • Accepted manuscript posted online 23 April 2014.
  • Copyright © 2014 Bossé et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.

REFERENCES

  1. 1.↵
    1. Bossé JT,
    2. Janson H,
    3. Sheehan BJ,
    4. Beddek AJ,
    5. Rycroft AN,
    6. Kroll JS,
    7. Langford PR
    . 2002. Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect. 4:225–235. doi:10.1016/S1286-4579(01)01534-9.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Blackall PJ,
    2. Klaasen HL,
    3. Van Den Bosch H,
    4. Kuhnert P,
    5. Frey J
    . 2002. Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Vet. Microbiol. 84:47–52. doi:10.1016/S0378-1135(01)00428-X.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Dubreuil JD,
    2. Jacques M,
    3. Mittal KR,
    4. Gottschalk M
    . 2000. Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Anim. Health Res. Rev. 1:73–93. doi:10.1017/S1466252300000074.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. O'Neill C,
    2. Jones SCP,
    3. Bossé JT,
    4. Watson CM,
    5. Williamson SM,
    6. Rycroft AN,
    7. Kroll JS,
    8. Hartley HM,
    9. Langford PR
    . 2010. Prevalence of Actinobacillus pleuropneumoniae serovars in England and Wales. Vet. Rec. 167:161–162. doi:10.1136/vr.b4884.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Klitgaard K,
    2. Friis C,
    3. Angen Ø,
    4. Boye M
    . 2010. Comparative profiling of the transcriptional response to iron restriction in six serotypes of Actinobacillus pleuropneumoniae with different virulence potential. BMC Genomics 11:698. doi:10.1186/1471-2164-11-698.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Fussing V
    . 1998. Genomic relationships of Actinobacillus pleuropneumoniae serotype 2 strains evaluated by ribotyping, sequence analysis of ribosomal intergenic regions, and pulsed-field gel electrophoresis. Lett. Appl. Microbiol. 27:211–215.
    OpenUrlPubMed
  7. 7.↵
    1. Møller K,
    2. Nielsen R,
    3. Andersen LV,
    4. Kilian M
    . 1992. Clonal analysis of the Actinobacillus pleuropneumoniae population in a geographically restricted area by multilocus enzyme electrophoresis. J. Clin. Microbiol. 30:623–627.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Mittal KR
    . 1990. Cross-reactions between Actinobacillus (Haemophilus) pleuropneumoniae strains of serotypes 1 and 9. J. Clin. Microbiol. 28:535–539.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mittal KR,
    2. Bourdon S
    . 1991. Cross-reactivity and antigenic heterogeneity among Actinobacillus pleuropneumoniae strains of serotypes 4 and 7. J. Clin. Microbiol. 29:1344–1347.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Zhou L,
    2. Jones SC,
    3. Angen Ø,
    4. Bossé JT,
    5. Nash JH,
    6. Frey J,
    7. Zhou R,
    8. Chen HC,
    9. Kroll JS,
    10. Rycroft AN,
    11. Langford PR
    . 2008. A multiplex PCR that can distinguish between immunologically cross-reactive serovar 3, 6 and 8 Actinobacillus pleuropneumoniae strains. J. Clin. Microbiol. 46:800–803. doi:10.1128/JCM.01787-07.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Jessing SG,
    2. Angen Ø,
    3. Inzana TJ
    . 2003. Evaluation of a multiplex PCR test for simultaneous identification and serotyping of Actinobacillus pleuropneumoniae serotypes 2, 5, and 6. J. Clin. Microbiol. 41:4095–4100. doi:10.1128/JCM.41.9.4095-4100.2003.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Schuchert JA,
    2. Inzana TJ,
    3. Angen Ø,
    4. Jessing S
    . 2004. Detection and identification of Actinobacillus pleuropneumoniae serotypes 1, 2, and 8 by multiplex PCR. J. Clin. Microbiol. 42:4344–4348. doi:10.1128/JCM.42.9.4344-4348.2004.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Angen Ø Ahrens P,
    2. Jessing SG
    . 2008. Development of a multiplex PCR test for identification of Actinobacillus pleuropneumoniae serovars 1, 7, and 12. Vet. Microbiol. 132:312–318. doi:10.1016/j.vetmic.2008.05.010.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Ito H,
    2. Katsuragi K,
    3. Akama S,
    4. Yuzawa H
    . 2014. Isolation of atypical genotype Actinobacillus pleuropneumoniae Serotype 6 in Japan. J. Vet. Med. Sci. 76:601–604. doi:10.1292/jvms.13-0245.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Quail MA,
    2. Kozarewa I,
    3. Smith F,
    4. Scally A,
    5. Stephens PJ,
    6. Durbin R,
    7. Swerdlow H,
    8. Turner DJ
    . 2008. A large genome center's improvements to the Illumina sequencing system. Nat. Methods 5:1005–1010. doi:10.1038/nmeth.1270.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Quail MA,
    2. Swerdlow H,
    3. Turner DJ
    . 2009. Improved protocols for the Illumina genome analyzer sequencing system. Curr. Protoc. Hum. Genet. Chapter 18:Unit 18.2. doi:10.1002/0471142905.hg1802s62.
    OpenUrlCrossRef
  17. 17.↵
    1. Zerbino DR,
    2. Birney E
    . 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18:821–829. doi:10.1101/gr.074492.107.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Altschul SF,
    2. Gish W,
    3. Miller W,
    4. Myers EW,
    5. Lipman DJ
    . 1990. Basic local alignment search tool. J. Mol. Biol. 215:403–410.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Xu Z,
    2. Zhou Y,
    3. Li L,
    4. Zhou R,
    5. Xiao S,
    6. Wan Y,
    7. Zhang S,
    8. Wang K,
    9. Li W,
    10. Li L,
    11. Jin H,
    12. Kang M,
    13. Dalai B,
    14. Li T,
    15. Liu L,
    16. Cheng Y,
    17. Zhang L,
    18. Xu T,
    19. Zheng H,
    20. Pu S,
    21. Wang B,
    22. Gu W,
    23. Zhang XL,
    24. Zhu GF,
    25. Wang S,
    26. Zhao GP,
    27. Chen H
    . 2008. Genome biology of Actinobacillus pleuropneumoniae JL03, an isolate of serotype 3 prevalent in China. PLoS One 3:e1450. doi:10.1371/journal.pone.0001450.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Xu ZF,
    2. Chen XB,
    3. Li L,
    4. Li TT,
    5. Wang SY,
    6. Chen HC,
    7. Zhou R
    . 2010. Comparative genomic characterization of Actinobacillus pleuropneumoniae. J. Bacteriol. 192:5625–5636. doi:10.1128/JB.00535-10.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Zhan B,
    2. Angen Ø,
    3. Hedegaard J,
    4. Bendixen C,
    5. Panitz F
    . 2010. Draft genome sequences of Actinobacillus pleuropneumoniae serotypes 2 and 6. J. Bacteriol. 192:5846–5847. doi:10.1128/JB.00867-10.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Zhou L,
    2. Jones SCP,
    3. Angen Ø,
    4. Bossé JT,
    5. Nash J,
    6. Zhou R,
    7. Chen H,
    8. Frey J,
    9. Kroll JS,
    10. Rycroft AN,
    11. Langford PR
    . 2008. PCR specific for Actinobacillus pleuropneumoniae serotype 3. Vet. Rec. 162:648–652. doi:10.1136/vr.162.20.648.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Tegetmeyer HE,
    2. Jones SC,
    3. Langford PR,
    4. Baltes N
    . 2008. ISApl1, a novel insertion element of Actinobacillus pleuropneumoniae, prevents ApxIV-based serological detection of serotype 7 strain AP76. Vet. Microbiol. 128:342–353. doi:10.1016/j.vetmic.2007.10.025.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Animal Health and Veterinary Laboratories Agency (AHVLA). 2012. Emerging threats quarterly report: pig diseases. Quarterly report: pigs. January-March 2012. AHVLA, Surrey, United Kingdom. http://smartstore.bpex.org.uk/index.asp?302239.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Multiplex PCR Assay for Unequivocal Differentiation of Actinobacillus pleuropneumoniae Serovars 1 to 3, 5 to 8, 10, and 12
Janine T. Bossé, Yanwen Li, Øystein Angen, Lucy A. Weinert, Roy R. Chaudhuri, Matthew T. Holden, Susanna M. Williamson, Duncan J. Maskell, Alexander W. Tucker, Brendan W. Wren, Andrew N. Rycroft, Paul R. Langford on behalf of the BRaDP1T consortium
Journal of Clinical Microbiology Jun 2014, 52 (7) 2380-2385; DOI: 10.1128/JCM.00685-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Multiplex PCR Assay for Unequivocal Differentiation of Actinobacillus pleuropneumoniae Serovars 1 to 3, 5 to 8, 10, and 12
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multiplex PCR Assay for Unequivocal Differentiation of Actinobacillus pleuropneumoniae Serovars 1 to 3, 5 to 8, 10, and 12
Janine T. Bossé, Yanwen Li, Øystein Angen, Lucy A. Weinert, Roy R. Chaudhuri, Matthew T. Holden, Susanna M. Williamson, Duncan J. Maskell, Alexander W. Tucker, Brendan W. Wren, Andrew N. Rycroft, Paul R. Langford on behalf of the BRaDP1T consortium
Journal of Clinical Microbiology Jun 2014, 52 (7) 2380-2385; DOI: 10.1128/JCM.00685-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS AND DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X